NYSE · PRGOHealthcarePharmaceuticals

PERRIGO financials

$15.00−0.66%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 27
Q1 '26
Mar 28
Q4 '25
Dec 31
Q3 '25
Sep 27
Q2 '25
Jun 28
Q1 '25
Mar 29
Q4 '24
Dec 31
Q3 '24
Sep 28
Q2 '24
Jun 29
Q1 '24
Mar 30
Q4 '23
Dec 31
Q3 '23
Sep 30
Revenue$1.02B$969.2M$1.11B$1.04B$1.06B$1.04B$1.14B$1.09B$1.07B$1.08B$1.16B$1.12B
Gross profit$313.9M$325.5M$362.2M$377.1M$362.9M$392.3M$385.9M$404.4M$394.7M$357.7M$427.3M$411.2M
Gross margin30.7%33.6%32.6%36.1%34.4%37.6%33.9%37.2%37.0%33.1%36.9%36.6%
Operating income$23.6M-$372.3M-$1.29B$72.6M$45.4M$46.9M$114.2M$80.4M-$26.5M-$55.2M-$15.6M$62.1M
Net income$74.5M-$398.5M-$1.42B$7.5M-$8.4M-$6.4M-$44.5M-$21.0M-$108.4M$2.0M-$32.3M$14.2M
Net margin7.3%−41.1%−127.8%0.7%−0.8%−0.6%−3.9%−1.9%−10.2%0.2%−2.8%1.3%
Diluted EPS$0.53$-2.87$-10.19$0.05$-0.06$-0.05$-0.32$-0.15$-0.79$0.01$-0.24$0.10
EBITDA$134.8M$116.9M$170.3M$178.8M$141.9M$159.3M$245.1M$195.7M$126.4M$70.5M$90.9M$168.6M
Operating cash flow$82.7M-$113.6M$175.4M$51.7M$75.9M-$64.5M$312.6M$42.2M$9.5M-$1.4M$208.7M$124.5M
Free cash flow$68.4M-$127.4M$148.6M$29.8M$56.7M-$90.0M$274.9M$15.1M-$18.9M-$26.5M$182.0M$92.7M
Diluted shares139.6M138.7M139.2M138.9M138.2M137.7M137.4M137.5M137.1M137.6M132.8M136.9M

Balance sheet

Period endJun 27Mar 28Dec 31Sep 27Jun 28Mar 29
Cash & equivalents$399.7M$357.2M$531.6M$432.1M$454.2M$409.9M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$3.29B$3.63B$3.64B$3.64B$3.65B$3.63B
Total assets$7.61B$7.98B$8.54B$10.08B$10.09B$9.76B
Total liabilities$5.09B$5.48B$5.60B$5.64B$5.62B$5.40B
Shareholders' equity$2.52B$2.50B$2.94B$4.45B$4.47B$4.36B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology